Oruka Therapeutics (0H79) Ratios
Oruka Therapeutics Ratios
GB:0H79's free cash flow for Q2 2026 was $-33.15M. For the 2026 fiscal year, GB:0H79's free cash flow was increased by $0.00 and operating cash flow was $-33.15M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 22.37 | 28.89 | 37.72 | 15.56 | 14.28 |
| Quick Ratio | 22.37 | 28.89 | 37.72 | 15.56 | 14.28 |
| Cash Ratio | 3.05 | 4.72 | 37.50 | 15.25 | 14.02 |
| Solvency Ratio | -6.31 | -6.07 | -6.95 | -4.96 | -2.47 |
| Operating Cash Flow Ratio | -5.74 | -4.43 | -9.64 | -5.36 | -2.21 |
| Short-Term Operating Cash Flow Coverage | -142.50 | -271.54 | -105.94 | -187.62 | -188.41 |
| Net Current Asset Value | $ 327.17M | $ 363.07M | $ 41.29M | $ 50.54M | $ 46.06M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.04 | 1.03 | 1.08 | 1.08 |
| Debt Service Coverage Ratio | -170.19 | -48.92 | -95.26 | -192.31 | -192.72 |
| Interest Coverage Ratio | 0.00 | -60.03 | 0.00 | 0.00 | -1085.11 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.15 | 0.03 | 0.03 | 0.10 |
| Net Debt to EBITDA | 0.43 | 0.74 | 4.29 | 2.75 | 5.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 99.91% |
| EBT Per EBIT | 86.38% | 95.01% | 100.86% | 99.93% | 99.81% |
| Return on Assets (ROA) | -21.58% | -21.14% | -23.04% | -35.18% | -19.31% |
| Return on Equity (ROE) | -22.34% | -21.90% | -23.82% | -37.85% | -20.93% |
| Return on Capital Employed (ROCE) | -25.79% | -23.01% | -23.46% | -37.60% | -20.81% |
| Return on Invested Capital (ROIC) | -25.76% | -23.00% | -23.40% | -37.52% | -20.77% |
| Return on Tangible Assets | -21.58% | -21.14% | -23.04% | -35.18% | -19.31% |
| Earnings Yield | -7.63% | -25.72% | -2.42% | -5.39% | -4.30% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.02 | 0.01 | 0.34 | 0.08 | 0.05 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -18271.99 | -46801.11 | -1069.39 | -4480.27 | -6958.55 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 18271.99 | 46801.11 | 1069.39 | 4480.27 | 6958.55 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.93 | -3.44 | -0.76 | -1.35 | -1.64 |
| Free Cash Flow Per Share | -1.94 | -3.46 | -0.76 | -1.35 | -1.64 |
| Dividend Paid and CapEx Coverage Ratio | -422.06 | -0.18 | -5456.00 | -436.33 | -406.58 |
| Capital Expenditure Coverage Ratio | -422.06 | -306.02 | -5456.00 | -436.33 | -406.58 |
| Operating Cash Flow Coverage Ratio | -45.66 | -59.75 | -28.49 | -38.84 | -17.17 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -6.40% | -17.82% | -2.66% | -5.24% | -3.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.12 | -3.89 | -41.29 | -18.57 | -23.28 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.93 | 0.85 | 9.83 | 7.03 | 4.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.64 | -5.61 | -37.55 | -19.08 | -29.27 |
| Price-to-Operating Cash Flow Ratio | -15.67 | -5.63 | -37.56 | -19.12 | -29.34 |
| Price-to-Earnings Growth (PEG) Ratio | 0.24 | -0.31 | 0.82 | -0.19 | 0.28 |
| Enterprise Value Multiple | -12.70 | -3.22 | -37.48 | -15.90 | -18.46 |
| Enterprise Value | 1.34B | 264.94M | 367.76M | 305.84M | 178.04M |
| EV to EBITDA | -12.70 | -3.22 | -37.48 | -15.90 | -18.46 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -15.13 | -4.57 | -33.70 | -16.26 | -22.99 |
| EV to Operating Cash Flow | -15.16 | -4.58 | -33.70 | -16.30 | -23.05 |
| Tangible Book Value Per Share | 10.35 | 22.77 | 2.89 | 3.67 | 9.88 |
| Shareholders’ Equity Per Share | 10.35 | 22.77 | 2.89 | 3.67 | 9.88 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.31 | -4.99 | -0.69 | -1.39 | -2.07 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.02 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.84 | 0.69 | 1.10 | 0.97 | 0.79 |
Currency in USD